Page 6 - Fulcrum Therapeutics Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fulcrum therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fulcrum Therapeutics Inc Today - Breaking & Trending Today

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) VP Greg Tourangeau Sells 4,884 Shares of Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) VP Greg Tourangeau sold 4,884 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $11.72, for a total value of $57,240.48. Following the completion of the transaction, the vice president now owns 11,807 […] ....

United States , Piper Sandler , Greg Tourangeau , Fulcrum Therapeutics Inc , Group Plc , Securities Exchange Commission , Fulcrum Therapeutics Company Profile , Goldman Sachs Group , Manufacturers Life Insurance Company , Northern Trust Corp , Charles Schwab Investment Management Inc , Fulcrum Therapeutics , Get Free Report , Exchange Commission , Therapeutics Stock Down , General Group Plc , Schwab Investment Management , Trust Corp , Fulcrum Therapeutics Daily , Nasdaq Fulc , Insider Trading , Nsider Trades ,

Fulcrum Therapeutics (NASDAQ:FULC) Price Target Increased to $15.00 by Analysts at Piper Sandler

Fulcrum Therapeutics (NASDAQ:FULC – Free Report) had its price objective upped by Piper Sandler from $13.00 to $15.00 in a research note published on Wednesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the stock. Separately, The Goldman Sachs Group lifted their price target on shares of Fulcrum Therapeutics from $5.00 to […] ....

United States , Piper Sandler , Citigroup Inc , Fulcrum Therapeutics Company Profile , Tower Research Capital , Goldman Sachs Group , Fulcrum Therapeutics Inc , Proshare Advisors , Fulcrum Therapeutics , Free Report , Moderate Buy , Share Advisors , Research Capital , Get Free Report , Fulcrum Therapeutics Daily , Nasdaq Fulc , Boost Price Target ,

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Expected to Earn Q1 2024 Earnings of ($0.46) Per Share

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Expected to Earn Q1 2024 Earnings of ($0.46) Per Share
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Leerink Partnrs , Piper Sandler , Fulcrum Therapeutics Inc , Goldman Sachs Group , Manufacturers Life Insurance Company , Group Plc , Charles Schwab Investment Management Inc , Northern Trust Corp , Fulcrum Therapeutics , Free Report , Fulcrum Therapeutic , General Group Plc , Schwab Investment Management , Trust Corp , Get Free Report , Fulcrum Therapeutics Daily ,

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript

Fulcrum Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.44. ....

Michael Burry , Iain Fraser , Joseph Schwartz , Alex Sapir , Matthew Biegler , Corinne Johnson , Alan Musso , Fulcrum Therapeutics Inc , Goldman Sachs , Exchange Commission , Fulcrum Therapeutics , Call Transcript February , Fulcrum Therapeutics Fourth Quarter , Full Year , Business Update Conference , Private Security Litigation Reform Act , Joining Alex , Chief Financial Officer , Interim Chief Medical , Stock Picks , Joori Park , Chief Medical ,

Fulcrum Therapeutics (NASDAQ:FULC) Price Target Raised to $15.00

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) had its price objective hoisted by stock analysts at Piper Sandler from $13.00 to $15.00 in a report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s target price indicates a potential upside of 39.15% from the stock’s previous close. […] ....

United States , Piper Sandler , Proshare Advisors , Citigroup Inc , Fulcrum Therapeutics Company Profile , Fulcrum Therapeutics Inc , Goldman Sachs Group , Tower Research Capital , Fulcrum Therapeutics , Get Free Report , Share Advisors , Research Capital , Fulcrum Therapeutics Daily , Nasdaq Fulc , Boost Price Target ,